Women’s Health Market By Drug Class (Hormonal Therapies, Bone Health Agents, Fertility Agents, GnRH Modulators, Pain and Symptom Management, Metabolic Agents, Others); By Application (Hormonal Infertility, Contraceptives, Postmenopausal Osteoporosis, Endometriosis & Uterine Fibroids, Menopause, Polycystic Ovary Syndrome [PCOS], Others); By Age Group (Under 30 years, 31 to 50 years, 51 to 70 years, Above 70 years); By End User (Hospitals & Clinics, Diagnostic Centers, Home Healthcare, Online Retail & Pharmacies, Others) – Growth, Share, Opportunities & Competitive Analysis, 2024 – 2032
Global Women’s Health Market size was valued at USD 35,703.90 million in 2018 to USD 50,467.56 million in 2024 and is anticipated to reach USD 78,879.05 million by 2032, at a CAGR of 5.34% during the forecast period.
REPORT ATTRIBUTE
DETAILS
Historical Period
2020-2023
Base Year
2024
Forecast Period
2025-2032
Women’s Health Market Size 2024
USD 50,467.56 Million
Women’s Health Market, CAGR
5.34%
Women’s Health Market Size 2032
USD 78,879.05 Million
The global women’s health market is shaped by major players such as Abbott Laboratories, Bayer AG, Merck & Co., Inc., Pfizer, Inc., Teva Pharmaceuticals, Ferring B.V., Agile Therapeutics, Amgen, Inc., AstraZeneca PLC, Bristol-Myers Squibb Company, and F. Hoffmann-La Roche Ltd. These companies lead with strong portfolios in hormonal therapies, contraceptives, fertility treatments, and bone health agents. North America dominates the market with a 44.2% share in 2018, driven by advanced healthcare infrastructure and high adoption of women’s health products. Europe follows with 29.3% share, supported by robust regulatory frameworks, while Asia Pacific, with 18.5% share, emerges as the fastest-growing region due to rising healthcare investments and increasing demand for reproductive care solutions.
Access crucial information at unmatched prices!
Request your sample report today & start making informed decisions powered by Credence Research Inc.!
The global women’s health market was valued at USD 35,703.90 million in 2018, reached USD 50,467.56 million in 2024, and is projected to attain USD 78,879.05 million by 2032, registering a CAGR of 5.34%.
Key drivers include the rising prevalence of reproductive disorders, growing cases of postmenopausal osteoporosis, and increasing demand for contraceptives and fertility agents.
Market trends highlight the shift toward non-hormonal therapies, adoption of digital health platforms, and growing demand for long-acting contraceptives and advanced fertility treatments.
Competition remains strong with leading players such as Abbott, Bayer, Merck, Pfizer, Teva, Amgen, and Ferring focusing on product launches, clinical trials, and strategic partnerships to strengthen market presence.
Regional analysis shows North America held 44.2% share in 2018, followed by Europe at 29.3%, while Asia Pacific with 18.5% share is the fastest-growing region. By segment, contraceptives and hormonal therapies remain dominant revenue contributors globally.
Market Segmentation Analysis:
By Drug Class
Hormonal therapies hold the largest share in the women’s health market due to their broad use in contraceptives, menopause management, and infertility treatments. Strong demand arises from their effectiveness in regulating reproductive health and addressing hormonal imbalances. Bone health agents follow as a key sub-segment driven by rising cases of osteoporosis in aging women. Fertility agents and GnRH modulators are gaining traction with growing awareness of infertility treatments, while pain and symptom management solutions expand with rising endometriosis and menstrual disorder cases. Metabolic agents and others continue to support niche therapeutic needs.
For instance, once a top-selling product for Bayer with combined annual sales exceeding $1 billion, prescriptions for the contraceptives Yasmin and Yaz have significantly declined over the past decade due to safety concerns, extensive litigation, and competition from generic alternatives.
By Application and Age Group
Contraceptives dominate the application segment, accounting for the largest revenue share. Their use is driven by rising awareness of family planning, favorable government programs, and availability of hormonal and non-hormonal options. Postmenopausal osteoporosis treatment also shows steady growth due to aging populations. Within age group segmentation, women aged 31 to 50 years represent the dominant sub-segment, supported by higher usage of contraceptives, fertility treatments, and preventive healthcare services. Demand in the 51–70 years group is also significant, largely influenced by menopausal care and osteoporosis management.
For instance, NuvaRing, initially developed by Organon and now manufactured by Organon & Co. (after a series of acquisitions and spin-offs), was a highly popular non-oral contraceptive for many years.
By End User
Hospitals and clinics remain the largest end-user segment, holding a dominant share owing to their wide service coverage, specialized physicians, and advanced infrastructure for women’s healthcare. Diagnostic centers are expanding rapidly with increased adoption of preventive health checkups and fertility screenings. Home healthcare grows steadily, supported by remote monitoring tools and personalized care models. Online retail and pharmacies are emerging as strong channels, driven by consumer preference for convenience and discreet access to contraceptives and hormonal therapies. Other end users add incremental growth through community health programs and non-traditional care models.
Key Growth Drivers
Rising Prevalence of Chronic and Reproductive Health Disorders
The increasing burden of conditions such as osteoporosis, endometriosis, and polycystic ovary syndrome significantly drives the women’s health market. Rising infertility cases and hormonal imbalances further create consistent demand for advanced therapies. Aging populations amplify risks of postmenopausal osteoporosis and related complications. Pharmaceutical companies continue to introduce innovative drugs addressing these unmet needs. This growing prevalence ensures continuous adoption of treatment solutions, making chronic and reproductive health disorders a primary factor boosting market growth globally.
For instance, Amgen’s Prolia (denosumab) has been administered to more than 26 million women with osteoporosis worldwide since its initial launch in June 2010. The medication addresses postmenopausal bone loss, as well as osteoporosis in men and other at-risk patient populations.
Advancements in Hormonal and Non-Hormonal Therapies
Therapeutic innovation is a key growth driver as companies expand their portfolios of hormonal and non-hormonal treatments. Hormonal contraceptives and fertility drugs dominate the space, while newer non-hormonal products appeal to women seeking safer alternatives. Advancements in drug delivery, such as long-acting injectables and transdermal patches, enhance compliance and efficacy. Ongoing clinical trials aim to improve safety profiles, expanding treatment adoption across different age groups. These innovations strengthen accessibility and choice in healthcare, accelerating market growth.
For instance, Bayer’s Mirena intrauterine system is one of the most widely used hormonal intrauterine devices (IUDs) and is a highly effective, long-acting reversible contraceptive. Mirena is available in over 120 countries and is an important component of the overall market for intrauterine contraception, which is used by approximately 160 million women globally.
Government Initiatives and Awareness Programs
Supportive government policies and global awareness campaigns continue to drive adoption of women’s health products. Family planning initiatives, subsidies for contraceptives, and national osteoporosis screening programs boost early adoption. Public and private organizations actively promote awareness of infertility and reproductive health, increasing demand for specialized care. Programs in emerging economies play a critical role in bridging healthcare gaps for women. Combined, these efforts enhance healthcare infrastructure, expand coverage, and accelerate the growth of the women’s health market.
Key Trends & Opportunities
Rising Demand for Fertility and Reproductive Care Solutions
Fertility agents and assisted reproductive technologies are gaining strong momentum as infertility rates climb worldwide. Growing societal acceptance of IVF and related treatments expands the market scope. Advanced fertility drugs and diagnostics support success rates, attracting more women seeking parenthood later in life. Increasing medical tourism for affordable fertility care in Asia-Pacific creates cross-border opportunities. This trend strengthens demand for innovative therapies and positions reproductive care as a high-potential growth area in women’s healthcare.
For instance, Merck’s Gonal-f is a prominent fertility treatment, and the company reports that it has supported the birth of over 6 million babies worldwide.
Expansion of Digital Health and Online Pharmacies
Digital health platforms and online retail channels create new opportunities for women’s health solutions. Telemedicine offers easy access to gynecological consultations, while mobile apps track fertility and menopausal symptoms. Online pharmacies enhance access to contraceptives and hormonal therapies, particularly in regions with limited physical infrastructure. These channels provide privacy and convenience, encouraging wider adoption. Integration of digital tools with traditional care expands market reach, creating a strong opportunity for companies investing in technology-driven healthcare solutions.
Key Challenges
High Treatment Costs and Limited Accessibility
The cost of advanced therapies, fertility treatments, and long-term hormonal care limits adoption, especially in low- and middle-income regions. Despite government subsidies, affordability remains a major barrier for women in rural and underserved areas. Limited healthcare infrastructure and uneven availability of diagnostic facilities further reduce access to timely treatment. This challenge constrains overall market penetration and requires focused investments in affordable and inclusive healthcare delivery systems.
Safety Concerns and Regulatory Hurdles
Concerns around side effects of hormonal therapies and fertility agents act as barriers to wider adoption. Regulatory authorities enforce strict approval standards for women’s health drugs, often delaying product launches. Adverse effects such as cardiovascular risks or bone loss linked with certain treatments create hesitation among patients and providers. Meeting stringent clinical safety requirements increases costs and development timelines for companies. These regulatory and safety challenges continue to affect innovation speed and adoption in the global women’s health market.
Regional Analysis
North America
North America accounted for the largest share of the global women’s health market, representing 44.2% in 2018 with a market size of USD 15,793.44 million. The market grew to USD 22,095.20 million in 2024 and is projected to reach USD 34,628.69 million by 2032 at a CAGR of 5.4%. Growth is driven by strong healthcare infrastructure, high adoption of hormonal therapies, and supportive government programs in reproductive and menopausal care. Rising awareness of osteoporosis and fertility treatments further supports market dominance across the region.
Europe
Europe held a significant share of 29.3% in 2018, with market size at USD 10,477.31 million, advancing to USD 14,293.56 million in 2024. By 2032, it is expected to reach USD 21,078.27 million, growing at a CAGR of 4.6%. The region’s market expansion is supported by strict regulatory frameworks, rising healthcare spending, and strong demand for contraceptives and infertility treatments. Postmenopausal osteoporosis and PCOS therapies contribute to consistent revenue growth. High awareness and government-backed women’s health programs position Europe as the second-largest market globally.
Asia Pacific
Asia Pacific is the fastest-growing region, holding 18.5% share in 2018 with a market size of USD 6,589.51 million. It expanded to USD 10,128.59 million in 2024 and is forecasted to reach USD 18,010.85 million by 2032 at a CAGR of 7.0%. Rapid urbanization, rising infertility rates, and increasing adoption of modern contraceptives are major growth drivers. Expanding healthcare infrastructure in China, India, and Southeast Asia fosters accessibility to advanced treatments. Growing medical tourism for reproductive care further strengthens the region’s market outlook, making it the key growth engine globally.
Latin America
Latin America represented 4.3% of the global share in 2018, valued at USD 1,539.66 million. The market rose to USD 2,146.68 million in 2024 and is projected to reach USD 2,932.39 million by 2032 at a CAGR of 3.6%. Increasing government investments in healthcare and awareness campaigns on contraception and infertility management support gradual market growth. Brazil and Mexico drive the majority of regional demand due to expanding access to diagnostic services and reproductive health facilities. However, limited healthcare access in rural areas slightly constrains growth potential across the region.
Middle East
The Middle East accounted for 2.4% share in 2018, with market value of USD 861.29 million, rising to USD 1,095.98 million in 2024. It is anticipated to reach USD 1,397.46 million by 2032 at a CAGR of 2.7%. Growing adoption of contraceptives, coupled with gradual improvements in healthcare access, drives demand. Fertility treatments are witnessing increased adoption in Gulf countries due to rising infertility cases. However, cultural and social barriers to women’s health treatments restrain rapid expansion. Market growth remains steady but slower compared to other developing regions.
Africa
Africa contributed 1.2% share in 2018, with market size of USD 442.69 million. It reached USD 707.56 million in 2024 and is projected to grow to USD 831.39 million by 2032 at a CAGR of 1.6%, the slowest globally. Limited healthcare infrastructure, affordability challenges, and low access to modern therapies hinder widespread adoption. However, increasing initiatives by international organizations and gradual improvements in urban healthcare access provide opportunities for growth. Contraceptives and maternal care programs drive most of the demand, though penetration remains limited compared to other global regions.
Market Segmentations:
By Drug Class
Hormonal Therapies
Bone Health Agents
Fertility Agents
GnRH Modulators
Pain and Symptom Management
Metabolic Agents
Others
By Application
Hormonal Infertility
Contraceptives
Postmenopausal Osteoporosis
Endometriosis & Uterine Fibroids
Menopause
Polycystic Ovary Syndrome (PCOS)
Others
By Age Group
Under 30 years
31 to 50 years
51 to 70 years
Above 70 years
By End User
Hospitals & Clinics
Diagnostic Centers
Home Healthcare
Online Retail & Pharmacies
Others
By Geography
North America
Europe
Asia Pacific
Latin America
Middle East
Africa
Competitive Landscape
The global women’s health market is highly competitive, with leading pharmaceutical and biotechnology companies driving innovation across therapeutic areas. Key players include Abbott Laboratories, Bayer AG, Merck & Co., Inc., Pfizer, Inc., Teva Pharmaceuticals, Ferring B.V., Agile Therapeutics, Amgen, Inc., AstraZeneca PLC, Bristol-Myers Squibb Company, and F. Hoffmann-La Roche Ltd. These companies hold strong portfolios spanning hormonal therapies, fertility treatments, contraceptives, and osteoporosis management solutions. Strategic priorities include expanding product pipelines, securing regulatory approvals, and enhancing global distribution networks. Recent developments emphasize partnerships, acquisitions, and the introduction of advanced non-hormonal therapies aimed at reducing side effects and improving patient compliance. Companies also focus on digital health integration and online pharmacy collaborations to strengthen consumer outreach. Intense competition encourages continuous investment in research and development, with players striving to capture demand from emerging regions while maintaining leadership in mature markets.
Shape Your Report to Specific Countries or Regions & Enjoy 30% Off!
In September 2024, Organon announced acquisition of Dermavant, a subsidiary of Roivant focused on developing and commercializing novel treatments in immuno-dermatology.
In March 2024, Insud Pharma announced the successful acquisition of Viatris’ Women’s Healthcare division, which focuses on oral and injectable contraceptives. This strategic move strengthens Insud Pharma’s industrial footprint in India by adding two manufacturing facilities located in Sarigam and Ahmedabad.
In March 2024, The U.S. FDA granted approval to ELAHERE, developed by AbbVie Inc., for the treatment of adult patients with folate receptor alpha (FRα)-positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer, who have previously undergone up to three lines of therapy.
In December 2023, Theramex completed the acquisition of the Femoston and Duphaston in Europe from Viatris. The company acquired these products for the consolidation of its menopause portfolio.
Report Coverage
The research report offers an in-depth analysis based on Drug Class, Application, Age Group, End User and Geography. It details leading market players, providing an overview of their business, product offerings, investments, revenue streams, and key applications. Additionally, the report includes insights into the competitive environment, SWOT analysis, current market trends, as well as the primary drivers and constraints. Furthermore, it discusses various factors that have driven market expansion in recent years. The report also explores market dynamics, regulatory scenarios, and technological advancements that are shaping the industry. It assesses the impact of external factors and global economic changes on market growth. Lastly, it provides strategic recommendations for new entrants and established companies to navigate the complexities of the market.
Future Outlook
The women’s health market will expand steadily with rising focus on reproductive care.
Demand for contraceptives will remain dominant due to increasing family planning awareness.
Fertility treatments will grow strongly as infertility rates rise across developed and emerging regions.
Advancements in non-hormonal therapies will gain traction for safer treatment alternatives.
Digital health platforms will play a larger role in diagnosis and remote consultations.
North America will maintain leadership while Asia Pacific emerges as the fastest-growing region.
Aging populations will drive higher adoption of osteoporosis and menopause-related therapies.
Strategic collaborations and acquisitions will shape competition among global pharmaceutical leaders.
Online pharmacies will expand access to women’s health products and therapies.
Increasing government initiatives will support wider availability of preventive and specialized care.
CHAPTER NO. 1: GENESIS OF THE MARKET
1.1 Market Prelude – Introduction & Scope
1.2 The Big Picture – Objectives & Vision
1.3 Strategic Edge – Unique Value Proposition
1.4 Stakeholder Compass – Key Beneficiaries CHAPTER NO. 2: EXECUTIVE LENS
2.1 Pulse of the Industry – Market Snapshot
2.2 Growth Arc – Revenue Projections (USD Million)
2.3. Premium Insights – Based on Primary Interviews CHAPTER NO. 3: WOMEN’S HEALTH MARKET FORCES & INDUSTRY PULSE
3.1 Foundations of Change – Market Overview
3.2 Catalysts of Expansion – Key Market Drivers
3.2.1 Momentum Boosters – Growth Triggers
3.2.2 Innovation Fuel – Disruptive Technologies
3.3 Headwinds & Crosswinds – Market Restraints
3.3.1 Regulatory Tides – Compliance Challenges
3.3.2 Economic Frictions – Inflationary Pressures
3.4 Untapped Horizons – Growth Potential & Opportunities
3.5 Strategic Navigation – Industry Frameworks
3.5.1 Market Equilibrium – Porter’s Five Forces
3.5.2 Ecosystem Dynamics – Value Chain Analysis
3.5.3 Macro Forces – PESTEL Breakdown
3.6 Price Trend Analysis
3.6.1 Regional Price Trend
3.6.2 Price Trend by Product
CHAPTER NO. 4: KEY INVESTMENT EPICENTER
4.1 Regional Goldmines – High-Growth Geographies
4.2 Product Frontiers – Lucrative Product Categories
4.3 Application Sweet Spots – Emerging Demand Segments CHAPTER NO. 5: REVENUE TRAJECTORY & WEALTH MAPPING
5.1 Momentum Metrics – Forecast & Growth Curves
5.2 Regional Revenue Footprint – Market Share Insights
5.3 Segmental Wealth Flow – Drug Class & Age Group Revenue CHAPTER NO. 6: TRADE & COMMERCE ANALYSIS
6.1. Import Analysis by Region
6.1.1. Global Women’s Health Market Import Revenue By Region
6.2. Export Analysis by Region
6.2.1. Global Women’s Health Market Export Revenue By Region CHAPTER NO. 7: COMPETITION ANALYSIS
7.1. Company Market Share Analysis
7.1.1. Global Women’s Health Market: Company Market Share
7.2. Global Women’s Health Market Company Revenue Market Share
7.3. Strategic Developments
7.3.1. Acquisitions & Mergers
7.3.2. New Product Launch
7.3.3. Regional Expansion
7.4. Competitive Dashboard
7.5. Company Assessment Metrics, 2024 CHAPTER NO. 8: WOMEN’S HEALTH MARKET – BY DRUG CLASS SEGMENT ANALYSIS
8.1. Women’s Health Market Overview by Drug Class Segment
8.1.1. Women’s Health Market Revenue Share By Drug Class
8.2. Hormonal Therapies
8.3. Bone Health Agents
8.4. Fertility Agents
8.5. GnRH Modulators
8.6. Pain and Symptom Management
8.7. Metabolic Agents
8.8. Others CHAPTER NO. 9: WOMEN’S HEALTH MARKET – BY APPLICATION SEGMENT ANALYSIS
9.1. Women’s Health Market Overview by Application Segment
9.1.1. Women’s Health Market Revenue Share By Application
9.2. Hormonal Infertility
9.3. Contraceptives
9.4. Postmenopausal Osteoporosis
9.5. Endometriosis & Uterine Fibroids
9.6. Menopause
9.7. Polycystic Ovary Syndrome (PCOS)
9.8. Others CHAPTER NO. 10: WOMEN’S HEALTH MARKET – BY AGE GROUP SEGMENT ANALYSIS
10.1. Women’s Health Market Overview by Age Group Segment
10.1.1. Women’s Health Market Revenue Share By Age Group
10.2. Under 30 years
10.3. 31 to 50 years
10.4. 51 to 70 years
10.5. Above 70 years CHAPTER NO. 11: WOMEN’S HEALTH MARKET – BY END USER SEGMENT ANALYSIS
11.1. Women’s Health Market Overview by End User Segment
11.1.1. Women’s Health Market Revenue Share By End User
11.2. Hospitals & Clinics
11.3. Diagnostic Centers
11.4. Home Healthcare
11.5. Online Retail & Pharmacies
11.6. Others CHAPTER NO. 12: WOMEN’S HEALTH MARKET – REGIONAL ANALYSIS
12.1. Women’s Health Market Overview by Region Segment
12.1.1. Global Women’s Health Market Revenue Share By Region
12.1.2. Regions
12.1.3. Global Women’s Health Market Revenue By Region
12.1.4. Drug Class
12.1.5. Global Women’s Health Market Revenue By Drug Class
12.1.6. Application
12.1.7. Global Women’s Health Market Revenue By Application
12.1.8. Age Group
12.1.9. Global Women’s Health Market Revenue By Age Group
12.1.10. End User
12.1.11. Global Women’s Health Market Revenue By End User CHAPTER NO. 13: NORTH AMERICA WOMEN’S HEALTH MARKET – COUNTRY ANALYSIS
13.1. North America Women’s Health Market Overview by Country Segment
13.1.1. North America Women’s Health Market Revenue Share By Region
13.2. North America
13.2.1. North America Women’s Health Market Revenue By Country
13.2.2. Drug Class
13.2.3. North America Women’s Health Market Revenue By Drug Class
13.2.4. Application
13.2.5. North America Women’s Health Market Revenue By Application
13.2.6. Age Group
13.2.7. North America Women’s Health Market Revenue By Age Group
13.2.8. End User
13.2.9. North America Women’s Health Market Revenue By End User
13.3. U.S.
13.4. Canada
13.5. Mexico CHAPTER NO. 14: EUROPE WOMEN’S HEALTH MARKET – COUNTRY ANALYSIS
14.1. Europe Women’s Health Market Overview by Country Segment
14.1.1. Europe Women’s Health Market Revenue Share By Region
14.2. Europe
14.2.1. Europe Women’s Health Market Revenue By Country
14.2.2. Drug Class
14.2.3. Europe Women’s Health Market Revenue By Drug Class
14.2.4. Application
14.2.5. Europe Women’s Health Market Revenue By Application
14.2.6. Age Group
14.2.7. Europe Women’s Health Market Revenue By Age Group
14.2.8. End User
14.2.9. Europe Women’s Health Market Revenue By End User
14.3. UK
14.4. France
14.5. Germany
14.6. Italy
14.7. Spain
14.8. Russia
14.9. Rest of Europe CHAPTER NO. 15: ASIA PACIFIC WOMEN’S HEALTH MARKET – COUNTRY ANALYSIS
15.1. Asia Pacific Women’s Health Market Overview by Country Segment
15.1.1. Asia Pacific Women’s Health Market Revenue Share By Region
15.2. Asia Pacific
15.2.1. Asia Pacific Women’s Health Market Revenue By Country
15.2.2. Drug Class
15.2.3. Asia Pacific Women’s Health Market Revenue By Drug Class
15.2.4. Application
15.2.5. Asia Pacific Women’s Health Market Revenue By Application
15.2.6. Age Group
15.2.7. Asia Pacific Women’s Health Market Revenue By Age Group
15.2.8. End User
15.2.9. Asia Pacific Women’s Health Market Revenue By End User
15.3. China
15.4. Japan
15.5. South Korea
15.6. India
15.7. Australia
15.8. Southeast Asia
15.9. Rest of Asia Pacific CHAPTER NO. 16: LATIN AMERICA WOMEN’S HEALTH MARKET – COUNTRY ANALYSIS
16.1. Latin America Women’s Health Market Overview by Country Segment
16.1.1. Latin America Women’s Health Market Revenue Share By Region
16.2. Latin America
16.2.1. Latin America Women’s Health Market Revenue By Country
16.2.2. Drug Class
16.2.3. Latin America Women’s Health Market Revenue By Drug Class
16.2.4. Application
16.2.5. Latin America Women’s Health Market Revenue By Application
16.2.6. Age Group
16.2.7. Latin America Women’s Health Market Revenue By Age Group
16.2.8. End User
16.2.9. Latin America Women’s Health Market Revenue By End User
16.3. Brazil
16.4. Argentina
16.5. Rest of Latin America CHAPTER NO. 17: MIDDLE EAST WOMEN’S HEALTH MARKET – COUNTRY ANALYSIS
17.1. Middle East Women’s Health Market Overview by Country Segment
17.1.1. Middle East Women’s Health Market Revenue Share By Region
17.2. Middle East
17.2.1. Middle East Women’s Health Market Revenue By Country
17.2.2. Drug Class
17.2.3. Middle East Women’s Health Market Revenue By Drug Class
17.2.4. Application
17.2.5. Middle East Women’s Health Market Revenue By Application
17.2.6. Age Group
17.2.7. Middle East Women’s Health Market Revenue By Age Group
17.2.8. End User
17.2.9. Middle East Women’s Health Market Revenue By End User
17.3. GCC Countries
17.4. Israel
17.5. Turkey
17.6. Rest of Middle East CHAPTER NO. 18: AFRICA WOMEN’S HEALTH MARKET – COUNTRY ANALYSIS
18.1. Africa Women’s Health Market Overview by Country Segment
18.1.1. Africa Women’s Health Market Revenue Share By Region
18.2. Africa
18.2.1. Africa Women’s Health Market Revenue By Country
18.2.2. Drug Class
18.2.3. Africa Women’s Health Market Revenue By Drug Class
18.2.4. Application
18.2.5. Africa Women’s Health Market Revenue By Application
18.2.6. Age Group
18.2.7. Africa Women’s Health Market Revenue By Age Group
18.2.8. End User
18.2.9. Africa Women’s Health Market Revenue By End User
18.3. South Africa
18.4. Egypt
18.5. Rest of Africa CHAPTER NO. 19: COMPANY PROFILES
19.1. Abbott Laboratories
19.1.1. Company Overview
19.1.2. Product Portfolio
19.1.3. Financial Overview
19.1.4. Recent Developments
19.1.5. Growth Strategy
19.1.6. SWOT Analysis
19.2. Bayer AG
19.3. Merck & Co., Inc.
19.4. Pfizer, Inc.
19.5. Teva Pharmaceuticals
19.6. Ferring B.V.
19.7. Agile Therapeutics
19.8. Amgen, Inc.
19.9. AstraZeneca PLC
19.10. Bristol-Myers Squibb Company
19.11. F. Hoffmann-La Roche Ltd
Request A Free Sample
We prioritize the confidentiality and security of your data. Our promise: your information remains private.
Ready to Transform Data into Decisions?
Request Your Sample Report and Start Your Journey of Informed Choices
Providing the strategic compass for industry titans.
Frequently Asked Questions:
What is the current market size for Global Women’s Health market, and what is its projected size in 2032?
The market size reached USD 50,467.56 million in 2024 and is projected to hit USD 78,879.05 million by 2032.
At what Compound Annual Growth Rate is the Global Women’s Health market projected to grow between 2025 and 2032?
The market is expected to grow at a CAGR of 5.34% during the forecast period.
Which Global Women’s Health market segment held the largest share in 2024?
The hormonal therapies segment held the largest share, driven by demand for contraceptives and menopause management.
What are the primary factors fueling the growth of the Global Women’s Health market?
Key factors include rising reproductive disorders, increasing cases of osteoporosis, and demand for contraceptives and fertility agents.
Who are the leading companies in the Global Women’s Health market?
Major players include Abbott, Bayer, Merck, Pfizer, Teva, Ferring, Amgen, Agile Therapeutics, AstraZeneca, Bristol-Myers Squibb, and Roche.
Which region commanded the largest share of the Global Women’s Health market in 2024?
North America led the market with the largest share, supported by strong healthcare infrastructure and high adoption of therapies.
About Author
Shweta Bisht
Healthcare & Biotech Analyst
Shweta is a healthcare and biotech researcher with strong analytical skills in chemical and agri domains.
Network Management Systems (NMS) Market size was valued at USD 10.75 Billion in 2024 and is anticipated to reach USD 22.21 Billion by 2032, at a CAGR of 9.5% during the forecast period.
Natural Fiber Reinforced Plastics Market size was valued at USD 9.98 Billion in 2024 and is anticipated to reach USD 24.36 Billion by 2032, at a CAGR of 11.8% during the forecast period.
Multifunctional Packaging Market size was valued at USD 12.74 billion in 2024 and is anticipated to reach USD 17.3 billion by 2032, at a CAGR of 3.9% during the forecast period.
The network monitoring market size was valued at USD 4.69 billion in 2024 and is anticipated to reach USD 13.2 billion by 2032, at a CAGR of 13.8 % during the forecast period (2024-2032).
Transformer Component Market size was valued at USD 5.3 billion in 2024 and is projected to reach USD 7.5 billion by 2032, growing at a CAGR of 4.5% during the forecast period.
The Transdermal Drug Delivery Systems Market was valued at USD 44.1 billion in 2024 and is projected to reach USD 101.6 billion by 2032, expanding at a CAGR of 11% during the forecast period.
Natural Surfactant Market size was valued at USD 22 billion in 2024 and is projected to reach USD 32.01 billion by 2032, growing at a CAGR of 4.8% during the forecast period.
Natural Sweeteners Market size was valued at USD 26.59 billion in 2024 and is projected to reach USD 43.71 billion by 2032, growing at a CAGR of 6.41% during the forecast period.
The network automation market size was valued at USD 6 billion in 2024 and is anticipated to reach USD 31.32 billion by 2032, at a CAGR of 22.95 % during the forecast period (2024-2032).
Licence Option
The report comes as a view-only PDF document, optimized for individual clients. This version is recommended for personal digital use and does not allow printing. Use restricted to one purchaser only.
$4999
To meet the needs of modern corporate teams, our report comes in two formats: a printable PDF and a data-rich Excel sheet. This package is optimized for internal analysis. Unlimited users allowed within one corporate location (e.g., regional office).
$6999
The report will be delivered in printable PDF format along with the report’s data Excel sheet. This license offers 100 Free Analyst hours where the client can utilize Credence Research Inc. research team. Permitted for unlimited global use by all users within the purchasing corporation, such as all employees of a single company.
Thank you for the data! The numbers are exactly what we asked for and what we need to build our business case.
Materials Scientist (privacy requested)
The report was an excellent overview of the Industrial Burners market. This report does a great job of breaking everything down into manageable chunks.
